about
Psychosurgery: past, present, and futureSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaFlip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replicationHypoxia enhances the replication of oncolytic herpes simplex virusDepletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic virusesTreatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Identification of diagnostic serum protein profiles of glioblastoma patientsAntiangiogenesis in neurofibromatosis 1.A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Anesthesia for suboccipital craniotomy in a patient with lymphangioleiomyomatosis: a case report.Oncolytic viral therapies - the clinical experience.Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumorsSingle agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastomaOncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.Oncolytic herpes simplex virus therapy for peripheral nerve tumors.Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological gradeMultifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpesThe added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyLong-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectorsExpression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.Postoperative imaging of vestibular schwannomas.Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts142 Genetic and Nongenetic Determinants of Cellular Architecture in IDH1-Mutant Oligodendrogliomas and Astrocytomas Using Single-Cell Transcriptome Analysis.Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
P50
Q22252336-C58C72A7-64E4-4292-BEEC-AEDB7DDC47A5Q29615604-6C85FEB1-7880-4525-810F-0F2A5B98542CQ30826113-590DBB42-AB10-4FE8-B3E8-9B6CB950D315Q33566587-11B86CFA-258D-4DBA-A7AE-609BD3CB4C5BQ33660631-E11CF976-0B16-4722-BA1D-CA2BE67B7283Q33773376-2DB4D1C4-A009-417F-AA3F-B5B4328323EAQ33894449-9E8CF18D-49DC-4E99-BEBD-C402D7577FF3Q34981475-520C5061-A904-4DB2-A58C-D549BADD5617Q34982037-A57FA41F-145C-4BCE-A2BC-CC3A1C03CB28Q35023915-D6E1E74A-D0C4-47A0-A1FC-00F639F7A7FCQ35091322-995ECEA8-7B79-4C94-85B7-02C01BE56182Q35648484-810D3CBA-435A-4F3B-9738-A919F80A194DQ35665220-FBF69D4D-DD0E-42CD-84FB-35B4598538F6Q35696355-3BB6670B-06AE-4B6F-88A0-70899CF78D86Q35759208-261B8F86-FE79-4708-AA5C-08950084155CQ35867997-2F2DE2CB-024C-4614-BCD4-574F72D4C7C6Q36168481-3194AC37-8A5A-4089-8AF1-CA0BA8CAB742Q36318202-9A56D56B-E820-46F5-BB5B-0D86DC022D01Q36512525-7D00E63D-08FC-4C70-B44A-EB8090B8A41AQ36575238-1828D258-872F-4EED-9D49-2F2320160506Q36861550-D8F67F64-588A-432E-A3CB-65DA18F0B340Q36871264-A5F5C6A1-39A8-46C7-B4CA-B956220B0D01Q36878711-7D43852A-72EF-4087-ADCB-0819E9B5396CQ36879211-0A9600AB-878C-4DB8-BB86-028B46EAE6DAQ36893234-68E3051E-00DC-4D17-857A-623ED3D8AC8BQ37031739-A253988A-33DE-4045-862B-ADDA480E4727Q37061120-C627F2F4-9963-4D7F-9E9B-3F74150BC59DQ37135872-03D29F5E-3D51-45FA-B69F-DD10F6FA5F98Q37140126-C00A38EB-CF47-4EEE-A3C3-AB7B229DC9C7Q37368850-681184AB-D23E-4532-995D-9547CA36C483Q37447217-08192011-1B84-42A2-A82F-34CAF419BDE2Q37579001-C9CBA72A-A52E-426C-8BC7-F66B8B52AD52Q38039462-EC4C5FC5-0F7E-4F9E-9981-66B00FD0EF88Q38400073-DE44084C-9919-41E5-A96A-912DE0B47744Q39004963-649702D2-2FBD-4F76-8077-71F2C3DC197DQ39462647-F3BAF878-6FB6-44F7-B20E-42A1303D33E6Q39614781-386C7286-F4E0-4A13-8EBF-41A3A1DF5B6EQ40073719-D895AA62-A956-4BB9-8D45-2A06AD871388Q40082476-5E21A4BD-0767-4470-91DD-EFAB622CEC4FQ40155173-76DF96E8-7D4D-4077-90A9-AEF48351BB7C
P50
name
Robert L Martuza
@en
type
label
Robert L Martuza
@en
prefLabel
Robert L Martuza
@en